Oncology Accelerated Approval In Spotlight (Again) With US FDA AdComm Review Of Incyte Retifanlimab For Anal Cancer

 
• By Bridget Silverman

US FDA questions suitability of accelerated approval based on marginal response rate in a single-arm trial of Incyte’s PD-1 inhibitor candidate for relapsed squamous carcinoma of the anal canal.

Business concept - high speed abstract MRT track of motion light for background in tokyo, japan

More from US FDA Performance Tracker

More from Regulatory Trackers